Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.
作者信息
Vincent L, Ceballos P, Plassot C, Méniane J C, Quittet P, Navarro R, Cyteval C, Szablewski V, Lu Z Y, Kanouni T, Moreaux J, Cartron G, Klein B, Fegueux N
机构信息
Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.
Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.
出版信息
Blood Cancer J. 2015 Aug 21;5(8):e341. doi: 10.1038/bcj.2015.48.
Abstract
摘要
相似文献
1
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.
Blood Cancer J. 2015 Aug 21;5(8):e341. doi: 10.1038/bcj.2015.48.
2
Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.
3
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
Bone Marrow Transplant. 2004 Dec;34(12):1057-65. doi: 10.1038/sj.bmt.1704713.
4
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5.
5
Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma.
Br J Haematol. 2014 Aug;166(4):616-8. doi: 10.1111/bjh.12881. Epub 2014 Apr 4.
6
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):242-5. doi: 10.1016/j.clml.2011.03.004. Epub 2011 Apr 8.
7
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Leukemia. 2008 Jun;22(6):1250-5. doi: 10.1038/leu.2008.88. Epub 2008 Apr 17.
8
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Bone Marrow Transplant. 2003 Dec;32(12):1145-51. doi: 10.1038/sj.bmt.1704289.
9
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002.
10
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Biol Blood Marrow Transplant. 2014 Aug;20(8):1211-6. doi: 10.1016/j.bbmt.2014.04.027. Epub 2014 May 2.
引用本文的文献
1
Multiple myeloma presenting as a cervical intraforaminal tumor: A case report and review of literature.
Front Surg. 2023 Jan 30;10:1011152. doi: 10.3389/fsurg.2023.1011152. eCollection 2023.
2
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
Int J Mol Sci. 2019 Mar 12;20(5):1248. doi: 10.3390/ijms20051248.
3
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.
本文引用的文献
1
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.
Haematologica. 2014 Apr;99(4):629-37. doi: 10.3324/haematol.2013.091918.
2
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.
3
Myeloma as a model for the process of metastasis: implications for therapy.
Blood. 2012 Jul 5;120(1):20-30. doi: 10.1182/blood-2012-01-379024. Epub 2012 Apr 24.
4
Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
J Clin Oncol. 2011 Oct 1;29(28):3805-12. doi: 10.1200/JCO.2011.34.9290. Epub 2011 Sep 6.
5
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.
BMC Cancer. 2010 May 13;10:198. doi: 10.1186/1471-2407-10-198.
6
Induction of angiogenesis by normal and malignant plasma cells.
Blood. 2009 Jul 2;114(1):128-43. doi: 10.1182/blood-2008-10-184226. Epub 2009 Mar 18.
7
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Bone Marrow Transplant. 2008 May;41(9):779-84. doi: 10.1038/sj.bmt.1705982. Epub 2008 Jan 14.
8
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii. doi: 10.1016/j.hoc.2007.08.007.
9
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
Leukemia. 2006 Mar;20(3):542-5. doi: 10.1038/sj.leu.2404085.
10
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Haematologica. 2005 Feb;90(2):278-9.
Zotero 插件